No Data
No Data
Express News | China Biopharmaceutical Co., Ltd. has annual revenue of RMB 26.20 billion and net profit of RMB 2.33 billion for the year of 2023.
SINO BIOPHARM: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Hong Kong pharmaceutical stocks bucked the trend, and Pharmacovigilance led their sector. Is the “Biosafety Act” or a biological variable?
① Why is the market paying attention to the Biosafety Act? ② How has Yao Ming Kangde performed recently?
Sino Biopharmaceutical's Diagnostic Agent Injection Gets Marketing Nod in China
Sino Biopharmaceutical (HKG:1177) said China's National Medical Products Administration gave the marketing approval to its Iopromide Injection, according to a Hong Kong bourse filing on Monday. The in
Featured announcements | Meituan Q4 revenue increased 22.6% year on year, adjusted net profit increased more than 4 times; Evergrande withdraws overseas debt restructuring application
Zijin Mining's net profit in 2023 was 21.119 billion yuan, up 5.38% year on year; Zhou Shengsheng's profit increased by about 124% last year; BAIC's annual net profit fell nearly 30%.
Express News | China Biopharmaceuticals announced on the Hong Kong Stock Exchange that the medical imaging product Iodopromide injection (trade name: polyiodine) developed by the Group has obtained marketing approval from the China National Drug Administration. As a dia
No Data